Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Poster Presentation to Focus on Reqorsa’s Ability to Modulate In Vivo Immune Responses Against Cancers AUSTIN, Texas, Oct. 7, 2024 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies…